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Context 
Cardiovascular disease (CVD) is a common and costly reason for hospitalisation and re-
hospitalisation among patients with type 2 diabetes.  
Objective 
This study aimed to develop and externally validate two risk prediction models for 
cardiovascular hospitalisation and cardiovascular re-hospitalisation. 
Design 
Two independent prospective cohorts. 
Setting 
The derivation cohort includes 4,704 patients with type 2 diabetes from 18 general practices in 
Cambridgeshire. The validation cohort comprises 1,121 patients with type 2 diabetes from post-
trial follow-up data.  
Main Outcome Measure 
Cardiovascular hospitalisation over 2 years and cardiovascular re-hospitalisation after 90 days of 
the prior CVD hospitalisation. 
Results 
The absolute rate of cardiovascular hospitalisation and re-hospitalisation was 12.5% and 6.7% in 
the derivation cohort, and 16.3% and 7.0% in the validation cohort. Discrimination of the models 
was similar in both cohorts, with C statistics above 0.70, and excellent calibration of observed 
and predicted risks.  
Conclusion 
Two new prediction models that quantify risks of cardiovascular hospitalisation and re-
hospitalisation have been developed and externally validated. They are based on a small number 
of clinical measurements that are available for patients with type 2 diabetes in many developed 
countries in primary care settings and could serve as the tools to screen the population at high 
risk of cardiovascular hospitalisation and re-hospitalisation. 
2 prediction models based on common clinical measurements have been developed and externally 
validated. They could aid real time decisions on prioritising more intensive diabetes management. 
MAIN TEXT 
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INTRODUCTION 
The prevalence and cost of diabetes is growing rapidly worldwide (1). People with diabetes are 
twice as likely to be admitted to hospital, and at least 10% of those in hospital have diabetes at 
any one time (2). In some age groups, it is as many as one in five (3). The associated costs of 
excess admissions, as well as increased costs per admission, are significant contributors to the 
financial burden borne by healthcare systems from diabetes and often reflect preventable 
morbidity suffered by patients (4).  
Previously, two prediction tools have been developed, both based on secondary care data, to 
identify those with diabetes, at high risk of either all-cause excessive length of stay or all-cause 
inpatient mortality over four years (5), or all-cause re-admission within 30 days among 
hospitalised patients (6). However, the practical application of both prediction models was 
limited by lack of external validation, non-specificity for people with type 2 diabetes, the use of 
predictors derived from secondary care rather than primary care data, variations on predictors 
recorded in different datasets (e.g. comorbidity) and a relative short time-gap between baseline 
and outcome (30 days’ readmission). 
Among hospital admissions, cardiovascular events are the major cause for hospitalisation in 
people with type 2 diabetes (7). Although risk factors such as blood pressure and HbA1c are 
recognised as warranting intervention on their own (8), (9), there has been no current algorithm 
to estimate the absolute risk of cardiovascular hospitalisation and rehospitalisation in people with 
type 2 diabetes.  
Using a model to make predictions for individual patients with type 2 diabetes is more 
comprehensive than using individual risk factors, and is preferred to the risk grouping approach 
(10), (11).  
The aim of our study was to develop and externally validate new prediction models based on 
reliable clinical measurements in primary care settings for cardiovascular hospitalisation over the 
next 2 years and cardiovascular re-hospitalisation up to 90 days following a prior cardiovascular 
hospitalisation. 
MATERIALS AND METHODS 
Data source and study population 
 We utilised two cohorts from Cambridgeshire, England: one (Derivation) based on the 
electronic health record data from primary care settings to develop our cardiovascular 
hospitalisation and re-hospitalisation risk scores and another (Validation) based on post-trial 
cohort data for external validation.  
Derivation cohort 
Patient lists from 18 general practices across Cambridgeshire, England, in 2008/2009 were 
collated and linked with hospital admissions (Secondary Uses Service (SUS)) data as part of an 
evaluation of diabetes care across the county by the local health board, National Health Service 
(NHS) Cambridgeshire. This cohort was limited to volunteer practices using the Egton Medical 
Information Systems (EMIS) general practitioner (GP) software system, from which a predefined 
set of data could be extracted. There was no systematic selection process for these surgeries, and 
data extracted were for their entire diabetes population. All patients with diabetes had follow-up 
hospitalisation data to 2010–2011. Hospital admissions to NHS and private hospitals within and 
outside Cambridgeshire were followed-up. No personal identifiers were released to researchers, 
and all subsequent analyses were conducted on anonymised datasets.  
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Validation cohort 
The design and methods of the RAPSID trial have been published previously (12), as have its 
CONSORT (Consolidated Standards of Reporting Trials) diagram and the results of its primary 
outcomes (12).  Briefly, RAPSID was a 2x2 factorial cluster RCT comparing 4 groups: Controls, 
1:1 (individual) peer support, group peer support, and combined 1:1 and group peer support 
among patients with type 2 diabetes. Participants had their diabetes for at least 12 months and 
those with dementia or psychotic illness were excluded. Participants were recruited from 
communities across Cambridgeshire and neighbouring areas of Essex and Hertfordshire.  Follow 
up data were only available for participants in Cambridgeshire and neighbouring areas of 
Hertfordshire that are served by the Cambridgeshire and Peterborough Clinical Commissioning 
Group (CCG). Clusters were defined by local government (‘parish council’) boundaries.  The 
intervention was developed following a pilot (13), using a framework defined by Peers for 
Progress (14).  Peers facilitating peer support were termed peer support facilitators and there 
selection, training, support and the overall programme are described elsewhere (15).      The 
intervention lasted 8-12 months and was commenced and concluded, cluster by cluster, between 
02/06/11 to 12/04/12.  Ethics approval was received from the Cambridgeshire REC2 Committee 
(10/H0308/72), and signed consent included agreement for access to hospital data.   
At baseline, demographic data, blood pressure, and HbA1c and lipid profiles information 
were collected. Each participant was followed up until June 2015 (0.91-4.07 years’ follow-up 
from beginning/entry into the trial).  Hospitalisation (NHS hospitals & private hospitals), 
Accident & Emergency (A&E) and outpatient visits within/outside Cambridgeshire and the 
included areas of Hertfordshire were completely collected through Cambridgeshire and 
Peterborough Clinical CCG (16) and the elective/non-elective status, and International 
Classification of Diseases (ICD-10) codes (8).  
Defining cardiovascular hospitalisation and re-hospitalisation 
The primary outcome of the study was having at least one hospitalisation with cardiovascular 
disease (CVD) as the primary diagnosis (ICD-10: I20–I25, I60–I69 and I73 in the first ICD field) 
over the 2-year follow-up and having at least one CVD re-hospitalisation after 90 days of prior 
CVD hospitalisation.  
Candidate predictors, missing data, and power calculations 
To achieve the maximum extrapolation application of our risk algorithm, objective clinical 
measurements were used as predictors in the model, including body mass index (BMI) , blood 
pressure (systolic (SBP) and diastolic (DBP))  and the metabolic variables glycated haemoglobin 
(HbA1c) and lipid profiles.  We also included demographic characteristics, (age and gender) and 
whether the patient was on lipid lowering treatment. Patients with diabetes were invited to have 
their blood pressure and metabolic variables measured at least once a year after the diagnosis of 
diabetes and the most recent was taken before 1 April 2009 (a minimum of 50 days before the 
first admission). Diabetes duration was not universally recorded, and hence was not usefully 
available for analysis. Diabetes therapy was not included in the dataset. Lipid-lowering treatment 
was recorded. 
Our derivation cohort had missing information on body mass index (3.17%), systolic blood 
pressure (9.95%), diastolic blood pressure (9.95%), total cholesterol (12.35%), high density 
lipoprotein (14.56%), and low density lipoprotein (16.27%). We used multiple imputation to 
replace missing values by using a chained equation approach based on all candidate predictors 
and outcomes. We created 16 imputed datasets for missing variables that were then combined 
across all datasets by using Rubin’s rule to obtain final model estimates. Limited information 
AD
VA
N
CE
 A
RT
IC
LE
:
TH
E 
JO
UR
NA
L 
O
F 
CL
IN
IC
AL
 
EN
D
O
CR
IN
O
LO
G
Y 
& 
M
ET
AB
O
LI
SM
JC
EM
Downloaded from https://academic.oup.com/jcem/advance-article-abstract/doi/10.1210/jc.2017-02293/4792932
by Keele University user
on 09 January 2018
AD
VA
NC
E 
AR
TI
CL
E
The Journal of Clinical Endocrinology & Metabolism; Copyright 2018  DOI: 10.1210/jc.2017-02293 
 
 
4
was missing (<1%) in our external validation dataset and the complete dataset was used in our 
analysis. On the basis of an estimated 588 cardiovascular hospitalisations and 316 cardiovascular 
re-hospitalisations and 16 predictors or levels in our derivation cohort, we had an effective 
sample size of 37 cardiovascular hospitalisation and 21 cardiovascular re-hospitalisation per 
predictor or level, above the minimum requirement suggested by Peduzzi et al (17). 
Ethical approval 
The derivation cohort work had approval from the Cambridgeshire research ethics committee as 
part of a wider service evaluation. Ethics approval for validation cohort was received from the 
Cambridgeshire REC2 Committee (10/H0308/72), and signed consent included agreement for 
access to hospital data.   
Statistical analysis for model derivation and external validation 
We treated incidence occurrence of cardiovascular hospitalization after the first 90 days since the 
start of follow-up and the incident occurrence of cardiovascular re-hospitalisation as binary 
outcome measures. For each of the 15 candidate predictors or levels, we used a univariate 
logistic regression model to calculate the unadjusted odds ratios. For derivation of the risk 
prediction model, we initially included all candidate predictors in a multivariable logistic 
regression model. We used fractional polynomials to model potential non-linear relationships 
between continuous predictors and outcome. 
Through backward elimination, we excluded lower lipid treatment from the multivariate 
model as it was not statistically significant (P>0.1 based on change in log likelihood). After 
elimination, we reinserted the excluded predictor into the final model to further check whether it 
became statistically significant. We also rechecked fractional polynomial terms at this stage and 
re-estimated them if necessary. We formed the risk equations for predicting the log odds of 
cardiovascular hospitalisation and cardiovascular re-hospitalisation by using the estimated 
regression coefficients multiplied by the corresponding predictors included in our models 
together with the intercepts. This process ultimately led to equations for the predicted 
risk=1/(1+e-riskscore), whether the “risk score” is the predicted log odds of cardiovascular 
hospitalisation or cardiovascular re-hospitalisation from the developed models. 
To facilitate model utilisation in clinical practice, the logistic regression equations were 
transformed into prognostic score charts. The coefficients in the logistic regression equation 
were multiplied by 50 and rounded to the nearest integer to obtain the prognostic score per 
predictor. Multiplication by 50 was chosen to get the majority of the coefficients close to an 
integer, thereby minimizing the effects of rounding. The sum of all prognostic scores reflects 
patients’ probability of cardiovascular hospitalisation or cardiovascular re-hospitalisation. 
We assessed the performance of the models in terms of the C statistics and calibration slope 
(where 1.00 is ideal). The C statistics represents the probability that for any randomly selected 
pair of people with type 2 diabetes with and without outcomes, the patient with outcomes had a 
higher predicted risk (18). A value of o.50 indicated no discrimination and 1.00 represents perfect 
discrimination. We then undertook internal validation to correct measures of predictive 
performance for optimism (over-fitting) by bootstrapping 100 samples of the derivation data. We 
repeated the model derivation process in each bootstrap sample to produce a model, applied the 
model to the same bootstrap sample to quantify apparent performance, and applied the model to 
the original dataset to test model performance (calibration slope and C-statistics) and optimism 
(difference in the test performance and apparent performance). We then estimated the overall 
optimism across all models.   
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We applied our risk prediction model to each patient with type 2 diabetes in the external 
validation cohort on the basis of the presence of one or more predictors. We examined the 
performance of this final model both in the derivation dataset and then in external validation 
dataset in terms of discrimination by calculating the C statistics. We examined calibration by 
plotting agreement between predicted and observed risks across tenth of the predicted risks.  
We used Stata V14.0 for all statistical analyses. This study was conducted and reported in 
line with the Transparent Reporting of a multivariate prediction model for Individual Prediction 
Diagnosis (TRIPOD) guidelines (19). 
Role of the funding source  
The sponsors of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report.  
RESULTS 
Study participants 
In our derivation cohort, we analysed information on 4,704 type 2 diabetes patients with 588 
cardiovascular hospitalisations within 2 years and 316 re-hospitalisations after 90 days since a 
prior cardiovascular hospitalisation. Our validated cohort had information on 1,121 type 2 
diabetes patients with 183 cardiovascular hospitalisations and 78 re-hospitalisations. Table-1 
summarises the basic characteristics and potential predictors of the study population. Patients 
with type 2 diabetes in both cohorts had similar age, gender, blood pressure and total cholesterol. 
Patients in the derived cohort had a higher level of high density lipoprotein, low density 
lipoprotein, and HbA1c. Compared with the derivation cohort, those in the validation cohort 
were more likely to be prescribed lowering lipid medicine and had more cardiovascular 
hospitalisation and re-hospitalisation.  
Model derivation, performance measure, and validation 
In the derivation dataset, the absolute risks of cardiovascular hospitalisation within 2 years and 
re-hospitalisation within 9o days post cardiovascular hospitalisation were 12.5% and 6.7%, 
respectively. Univariable associations between cardiovascular hospitalisation and cardiovascular 
re-hospitalisation are listed in supplemental Table-1. Of the 10 candidate predictors (16 
categories), 9 predictors (15 categories) were statistically significantly associated with 
cardiovascular hospitalisation and re-hospitalisation in the final multivariable model (Table-2). 
Table-2 shows apparent and internal validation performance statistics of the risk prediction 
model. After adjustment for optimism, the final risk prediction model was able to discriminate 
type 2 diabetes patients with and without cardiovascular hospitalisation with a C statistics of 
0.7094 (95% confidence interval 0.7067 to 0.7205), and discriminate type 2 diabetes patients 
with and without cardiovascular re-hospitalisation with a C statistics 0.7118 (0.7077 to 0.7159). 
The agreement between the observed and predicted proportion of cardiovascular hospitalisation 
and re-hospitalisation showed good apparent calibration (Figure-1, top left for cardiovascular 
hospitalisation and top right for cardiovascular re-hospitalisation). The optimism adjusted 
calibration slope was 1.0301 (0.9856 to 1.0747) and 1.0001 (0.9711 to 1.0247) for 
cardiovascular hospitalisation and re-hospitalisation, respectively (Table-3).  
External validation 
In the external validation cohort, the absolute risks for cardiovascular hospitalisation and re-
hospitalisation were 16.3% and 7.0%, respectively. Applying our final risk prediction model to 
the independent population gave a C statistic of 0.7092 (0.7033 to 0.7151) for cardiovascular 
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hospitalisation and 0.7098 (0.7014 to 0.7182) for cardiovascular re-hospitalisation, and good 
calibration (Figure-1, bottom left for cardiovascular hospitalisation and bottom right for 
cardiovascular re-hospitalisation), with the calibration slope 1.0001 (0.9807 to 1.0195) and 
0.9981 (0.9948 to 1.0482) for cardiovascular hospitalisation and re-hospitalisation, respectively. 
Performance at the threshold for 10% and 20% of patients at highest risk 
Table-4 shows the sensitivity, specificity, and observed risk for the 5%, 10%, 15%, 20% and 
25% of patients at the highest predicted risk of each outcome in the validation cohort shown for 
illustrative purposes. For example, when a risk threshold of 24.53% for cardiovascular 
hospitalisation and 7.93% for cardiovascular re-hospitalisation is used to identify the 20% at 
highest predicted risk, the sensitivity was 33.40% for cardiovascular hospitalisation and 45.20% 
for cardiovascular re-hospitalisation, the specificity was 84.60% for cardiovascular 
hospitalisation and 75.90% for cardiovascular rehospitalisation, and the observed risk was 
30.09% for cardiovascular hospitalisation and 11.98% for cardiovascular re-hospitalisation, 
respectively. 
Clinical examples 
Supplemental Chart-1 gives a clinical example of the application of prognostic score charts with 
graphical illustrations for cardiovascular hospitalisation and re-hospitalisation risk prediction 
models to predict 2-year risk of cardiovascular hospitalisation and risk of re-hospitalisation 
within 90 days of a prior cardiovascular hospitalisation.   
DISCUSSION 
We have developed two new risk prediction models to estimate the absolute risk of 
cardiovascular hospitalisation within 2 years and cardiovascular re-hospitalisation after 90 days 
of prior cardiovascular hospitalisation in a cohort of patients with type 2 diabetes in England. We 
then externally validated this model in another English cohort. The two prediction models had 
excellent calibration and useful discrimination, with C statistics of greater than 0.70 both in the 
derivation cohort and external validation cohort. The two prediction models were built from 
clinical variables usually recorded and accessible in primary care settings, implying that they can 
be readily applied in routine primary care. 
Strengths and limitations 
Our two risk algorithms have several advantages over those in utilisation in many developed 
countries. Our models are based on absolute risks determined and validated in two independent 
populations. The models are developed from routinely recorded demographic and clinical 
measurements in primary care settings, which suggests that they can be straightforwardly applied 
in general practice and are readily amenable for further external validations in countries that have 
routine recorded data accessible for such aims. And the two risk algorithms can be easily 
integrated into online calculators for implementation in general practices. 
The methods used to derive and validate the model are similar to those for other risk 
prediction algorithms derived from the CPRD and QResearch databases (20), (21). The majority of 
predictors in our final model are accurate and reliable clinical measurements (22) routinely 
recorded in primary care settings and updated and reviewed for patients with type 2 diabetes, and 
are less varied than in other datasets. Moreover, the proportion of missing values was low, which 
would lead to little variation in external applications, although multiple imputation was still 
applied in our study. We acknowledge that our prediction models do not take into account 
diabetes duration, antidiabetes treatments, anti-hypertensive treatments, prior history of 
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cardiovascular diseases, other diabetes complications (e.g. renal failure), lifestyle risk factors 
(like smoking), and other comorbidities due to limitations in the original data, but we feel that 
the clinical measurements included in our models could be proxies for missing predictors.  Data 
limitations also prevented extending our model to all diabetes complications rather than those 
relating to cardiovascular hospitalisation.  The relatively low sensitivities of our models to 
identify individuals at high risk of cardiovascular hospitalisation and re-hospitalisation is another 
limitation of the study. Due to the similarity between the derivation and validation cohorts, 
further external validation (e.g. cohorts from other countries) are warranted. 
Comparison with other studies 
Nirantharakumar et al. developed a prediction model among patients with diabetes to estimate 
adverse events (either excessive length of stay or inpatient mortality) over 4 years using a 
secondary care dataset in Birmingham, England (5). The predictors applied in this model covered 
demographic characteristics, clinical pathological test results, and use of insulin, recorded within 
72 hours of hospitalisation. That population represented the people with at least previous 
inpatient hospitalisation, and probably reflects a cohort with more severe conditions, and likely 
higher prior probabilities of an event. The ranges of clinical measurements during a hospital 
admission would tend to be greater than in the community, as patients would be sicker and e.g. 
blood glucose control could be the reason for hospitalisation, or exacerbated by acute illness, 
making the dataset difficult to use as a basis for a prediction tool in routine care. Most 
importantly, this prediction model has not been externally validated and the model performance 
needs to be further evaluated in external populations before its application in clinical practices.  
Rubin et al developed a tool to predict the risk of all-cause re-admission within 30 days 
among hospitalised patients with diabetes using hospitalised data (6). The short time-gap 
between predictor measurements and outcome made the tool less useful for clinical practice. The 
reasons for hospitalisation could be quite mixed, with different pathway and potential 
interventions. Therefore, using the all-cause hospitalisation risk as the outcome provides 
different information and allows less targeted interventions. As with Nirantharakumar et al’s 
model (5), this model has also not been externally validated in any independent population. 
Previous studies have not focussed on cardiovascular disease as both a major cause and cost 
for hospital admission among patients with diabetes. To understand the potential risk of 
cardiovascular hospitalisation in the next year, and the risk of a new episode (within 90 days) of 
a cardiovascular event (re-hospitalisation) could be helpful for clinicians to facilitate tailored, 
more intensive care to those with high risk profiles and to reduce hospitalisation inpatient cost. 
Conclusion and policy implication 
As far as we are aware, our study is the first study to develop prediction tools to estimate the 2-
year risk of cardiovascular hospitalisation and re-hospitalisation within 90 days of a previous 
hospitalisation. Our two prediction models have two important implications for clinical practice. 
First, they can be used as tools to screen populations at high risk of cardiovascular hospitalisation 
and re-hospitalisation. Both algorithms are based on readily accessible clinical data routinely 
recorded in primary care and reviewed by diabetes management teams.  They can be readily 
integrated into primary care computer systems or developed into an app for a handheld device 
for ease of use. Secondly, our risk prediction models could be used to establish new treatment 
thresholds in clinical practice through consensus development of national guidelines. 
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Figure-1. Assessing calibration in the derivation cohort (left) and the validation cohort (right) for 
cardiovascular hospitalisation (above panel) and cardiovascular re-hospitalisation (below panel) 
Table-1. Baseline Characteristics of study populations. 
  Derivation cohort External validation cohort 
N 4,704 1,121 
Cardiovascular hospitalisation, n (%) 588 (12.5) 183 (16.3) 
Cardiovascular rehospitalisation, n (%) 316 (6.7) 78 (7.0) 
Age, years 65.0±16.3 65.5±11.4 
Female, n (%) 1,919 (40.8) 444 (39.6) 
Systolic blood pressure, mmHg 134.5±16.0 139.7±20.2 
Diastolic blood pressure, mmHg 76.3±10.0 75.5±11.5 
Total cholesterol, mmol/L 4.3±1.2 4.2±1.7 
High density lipoprotein, mmol/L 1.3±0.6 1.1±1.2 
Low density lipoprotein, mmol/L 2.5±1.4 1.4±3.0 
Body mass index, kg/m2 30.8±6.9 32.2±6.0 
HbA1c, mmol/mol 61.5±17.2 56.2±15.1 
Lipid Lowering treatment, n (%) 3,342 (71.4) 731 (65.2) 
Table-2. Final multivariate analysis for cardiovascular hospitalisation and re-hospitalisation risk 
among people with type 2 diabetes in derivation cohort 
Predictors Coefficient 95% Confidence Interval 
Cardiovascular Hospitalisation 
Age ≥ 70 years 0.815914 (0.793045 to 0.838784) 
Male gender 0.228943 (0.206719 to 0.251168) 
HbA1c ≥ 57 mmol/mol (7.4%) -0.03967 (-0.06088 to -0.01846) 
(Body mass index/10)^-2 -1.85384 (-2.39533 to -1.31235) 
(Body mass index/10)^0.5 0.690585 (0.551284 to 0.829887) 
(Systolic blood pressure/100)^2 -0.40302 (-0.58492 to -0.22111) 
(Systolic blood pressure/100)^2*ln(Systolic blood 
pressure/100) 
0.966205 (0.758028 to 1.174381) 
(Diastolic blood pressure/100)^-2 0.474014 (0.387498 to 0.56053) 
(Diastolic blood pressure/100)^-2*ln(Diastolic blood 
pressure/100) 
0.2724 (0.188226 to 0.356575) 
ln(Total cholesterol/10) 0.514695 (0.27381 to 0.75558) 
(Total cholesterol/10)^0.5 -1.05803 (-1.86382 to -0.25223) 
ln(High density lipoprotein) 0.073489 (0.04377 to 0.103208) 
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11 
(High density lipoprotein)^3 -0.02384 (-0.02699 to -0.02069) 
(Low density lipoprotein/10)^0.5 -0.55634 (-0.67239 to -0.44028) 
ln(Low density lipoprotein/10)* (Low density 
lipoprotein/10)^0.5 
-0.83161 (-1.01001 to -0.65322) 
Constant -3.80246 (-4.67529 to -2.92963) 
Cardiovascular Re-hospitalisation 
Age ≥ 70 years 0.90054 (0.86384 to 0.93724) 
Male 0.22328 (0.188299 to 0.258261) 
HbA1c ≥ 57 mmol/mol (7.4%) 0.004076 (-0.0294 to 0.037547) 
(Body mass index/10)^-2 -4.17347 (-4.62492 to -3.72202) 
(Body mass index/10)^3 0.001821 (0.001318 to 0.002324) 
(Systolic blood pressure/100)^2 -1.16118 (-1.46728 to -0.85507) 
(Systolic blood pressure/100)^3 0.773551 (0.637616 to 0.909486) 
(Diastolic blood pressure/100)^-2 0.5875 (0.439237 to 0.735763) 
(Diastolic blood pressure/100)^-2*ln(Diastolic blood 
pressure/100) 
0.4095  (0.260667 to 0.558332) 
(Total cholesterol/10)^-2 -0.00798 (-0.01031 to -0.00565) 
(Total cholesterol/10)^2 -0.02734 (-0.23117 to 0.176482) 
ln(High density lipoprotein/10) 0.051443 (0.004285 to 0.0986) 
(High density lipoprotein/10)^3 -0.02718 (-0.03277 to -0.02159) 
Low density lipoprotein/10 -1.34491 (-1.56307 to -1.12675) 
ln(Low density lipoprotein/10) -0.88347  (-1.28497 to -0.48196) 
Constant -4.55873 (-4.8866 to -4.23086) 
Table-3. Model diagnostics (with 95% CI) 
 Derivation 
Validation Measure  Apparent performance Test performance Average optimism Optimism corrected 
 Cardiovascular Hospitalisation 
C statistic 0.7163 (0.7136 to 0.7190) 0.7027 (0.6996 to 0.7058) +0.0069 0.7094 (0.7067 to 0.7205) 
0.7092 (0.7033 to 
0.7151) 
Calibration slope 1.0000 (0.9806 to 1.0194) 0.9933 (0.9899 to 0.9966) +0.0067 0.9933 (0.9739 to 1.0127) 
1.0001 (0.9807 to 
1.0195) 
 Cardiovascular Re-hospitalisation 
C statistic 0.7154 (0.7113 to 0.7195) 0.7136 (0.7105 to 0.7167) +0.0036 0.7118 (0.7077 to 0.7159) 
0.7098 (0.7014 to 
0.7182) 
Calibration slope 1.0000 (0.9766 to 1.0234) 0.9976 (0.9949 to 1.0003) +0.0024 0.9976 (0.9742 to 0.9796) 
0.9981 (0.9948 to 
1.0482) 
Table-4. Predicted risk of cardiovascular hospitalisation and re-hospitalisation the validation 
cohort based on various cut-offs. 
  
Cut-off (%) for 
risk 
Mean 
predicted 
risk (%) Sensitivity (%) Specificity (%) 
Positive Predictive 
Value (%) 
Observed 
risk % 
Cardiovascular 
hospitalisation       
Top 5% 38.17 51.96 
10.30 (9.70 to 
10.90) 
97.40 (97.20 to 
97.50) 43.50 (41.50 to 45.50) 43.48 
Top 10% 31.73 43.35 
17.50 (16.80 to 
18.30) 
94.60 (94.40 to 
94.80) 38.60 (37.20 to 40.10) 38.62 
Top 15% 27.54 37.71 
24.70 (23.90 to 
25.60) 
90.10 (89.80 to 
90.40) 32.80 (31.80 to 33.90) 32.83 
Top 20% 24.53 33.77 
34.00 (33.10 to 
35.00) 
84.60 (84.20 to 
84.90) 30.10 (29.20 to 31.00) 30.09 
Top 25% 22.22 31.05 
42.80 (41.80 to 
43.80) 
78.40 (78.00 to 
78.70) 27.90 (27.20 to 28.60) 27.89 
Cardiovascular re-
hospitalisation        
Top 5% 11.34 15.86  
26.20 (24.90 to 
27.50)  
91.20 (91.00 to 
91.50)  18.30 (17.40 to 19.30)   18.33 
Top 10% 9.67 13.63 
34.50 (33.10 to 
36.00) 
84.30 (84.00 to 
84.60) 14.20 (13.50 to 14.90) 14.22 
Top 15% 8.69 12.59 40.50 (39.00 to 79.10 (78.80 to 12.70 (12.20 to 13.30) 12.73 
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42.00) 79.50) 
Top 20% 7.93 12.02 
45.20 (43.70 to 
46.70) 
75.90 (75.50 to 
76.30) 12.40 (11.90 to 12.90) 12.37 
Top 25% 7.16 11.46 
50.00 (48.50 to 
51.50) 
72.40 (72.00 to 
72.70) 12.00 (11.50 to 12.50) 11.98 
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